Core Insights - Polyrizon Ltd. announced results from a comparative study showing its naloxone formulation has superior nasal deposition compared to a commercial reference product [1][6]. Study Overview - The study was conducted at the University of Parma's Biopharmanet-TEC research center under the supervision of Prof. Fabio Sonvico, focusing on intranasal technologies [2]. - A validated silicone nasal cast model was used for the evaluation, combined with quantitative image analysis [3]. Key Findings - Polyrizon's formulation achieved 94.6% (±4.0%) deposition in the nasal vestibule and upper turbinate, compared to 79.6% (±3.0%) for the commercial product [9]. - The formulation showed significantly lower deposition in the lower turbinate region (5.4% vs. 20.4% for the commercial product), which may enhance dosing consistency and systemic delivery efficiency [9]. - The upper/anterior nasal region is critical for rapid systemic drug absorption, and Polyrizon's technology enables controlled regional deposition [5]. Company Technology - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [7]. - The proprietary Capture and Contain™ hydrogel technology aims to improve bioadhesion and retention at the nasal site for drug delivery [7]. - The company is advancing its naloxone program as part of a broader intranasal platform strategy [6].